Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates

It has been a busy week for the biotech sector, with earnings results. Biogen BIIB reported disappointing results for the fourth quarter. Concurrently, mergers and acquisitions continue to be in the spotlight as pharma and biotech majors look to bolster their product portfolio/pipeline.

Recap of the Week’s Most Important Stories:

Biogen’s Q4 Results: Biogen reported lower-than-expected results for the fourth quarter as both earnings and sales missed their respective estimates. Consequently, shares lost. Adjusted earnings per share (EPS) of $2.95 missed the Zacks Consensus Estimate of $3.16. Earnings also declined 27% year over year, attributable to closeout costs for Biogen’s controversial Alzheimer’s drug, Aduhelm, and lower revenues. On a constant currency basis, earnings were flat.

Total revenues came in at $2.39 billion, down 6% on a reported basis (5% on a constant-currency basis) from the year-ago quarter’s level. This was due to lower sales of all key drugs, multiple sclerosis drugs like Tecfidera and Tysabri, as well as spinal muscular atrophy drug, Spinraza. Sales missed the Zacks Consensus Estimate of $2.45 billion.

For 2024, revenues are expected to decline by a low to mid-single-digit percentage from the 2023 level. Core pharmaceutical revenues, comprising product sales plus Leqembi revenues, are expected to be flat year over year in 2024. Adjusted earnings are expected to be in the range of $15.00-$16.00, implying growth of approximately 5% at the midpoint of the guided range.

Biogen also announced that the European Commission (EC) has authorized Skyclarys (omaveloxolone) for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and above.

Gilead to Acquire CBAYGilead Sciences, Inc. GILD announced that it will acquire clinical-stage biopharmaceutical company, CymaBay Therapeutics, Inc. CBAY, for $32.50 per share in cash or a total equity value of $4.3 billion. Shares of CBAY surged on the acquisition news as the offer price represents 27% of the company’s closing share price as of Feb 9, 2024.

The acquisition, approved by both Gilead and CymaBay’s boards of directors, is expected to be closed in the ongoing quarter, subject to regulatory approvals and other customary closing conditions. The acquisition will add CymaBay’s investigational lead product candidate, seladelpar, to Gilead’s pipeline.

Seladelpar is an investigational, oral, selective peroxisome proliferator-activated receptor delta agonist, shown to regulate critical metabolic and liver disease pathways. The candidate is under review in the United States for the treatment of primary biliary cholangitis with a target action date of Aug 14, 2024. A potential approval will boost Gilead’s revenue growth. The transaction is likely to be neutral to Gilead’s bottom line in 2025 and significantly accretive thereafter.

Gilead has been looking to bolster its portfolio/pipeline since growth in its legacy HIV business slowed down and it suffered a few pipeline setbacks. However, investors probably deemed the deal to be expensive and the share price did not show any significant movement.

Gilead currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

VRTX, CRSP Win EC Nod for Casgevy: Vertex Pharmaceuticals VRTX and partner CRISPR Therapeutics CRSP announced that the EC has granted conditional marketing approval to their one-shot gene therapy, Casgevy, for treating two debilitating blood disorders — sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

The gene therapy is approved for patients 12 years and above with severe SCD characterized by recurrent vaso-occlusive crises or TDT, for whom hematopoietic stem cell (HSC) transplantation is appropriate and a human leukocyte antigen matched related HSC donor is not available. The FDA approved Casgevy for the SCD indication in December 2023 and for the TDT indication in January 2024.

CRISPR also announced that it will sell approximately $280 million of its common shares to a select group of institutional investors in a registered direct offering, at a price of $71.50 per share, representing a premium of greater than 10% to the company’s 30-day volume-weighted average price.

Performance

The Nasdaq Biotechnology Index has gained 0.24% in the past five trading sessions. Among the biotech giants, Moderna has lost 13.44% during the period. Over the past six months, shares of Vertex have surged 19.61%. (See the last biotech stock roundup here: Biotech Stock Roundup: GILD, AMGN & BMY’s Q4 Results, MOR Up on NVS Deal & More)

 

Zacks Investment Research
Image Source: Zacks Investment Research

What's Next in Biotech?

Stay tuned for more earnings and pipeline updates.


 

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.

It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Biogen Inc. (BIIB) : Free Stock Analysis Report

Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report

CymaBay Therapeutics Inc. (CBAY) : Free Stock Analysis Report

CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.